Evidence mapPaperPMID 39497340Full record

ArticleClinical and experimental dental research2024

Education and Communication on the Topic of Osteonecrosis of the Jaw When Taking Bone-Stabilizing Drugs.

Franz Gustav Saur, Christian Keinki, Alin Cramer, Jens Buentzel, Jutta Hübner

Abstract read
In one paragraph

Article in Clinical and experimental dental research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Franz Gustav SaurMedizinische Klinik II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.ORCID 0009-0009-6407-5662
Christian KeinkiDeutsche Krebsgesellschaft, Berlin, Germany.ORCID 0000-0001-9569-7346
Alin CramerMedizinische Klinik II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.
Jens BuentzelSüdharz klinikum, Klinik für HNO-Erkrankungen, Kopf-Hals-Chirurgie und Interdisziplinäre Palliativstation, Nordhausen, Germany.
Jutta HübnerMedizinische Klinik II, Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany.

Funding

The authors received no specific funding for this work.
6 · The paper itself

Abstract

objectivesThe aim of this study was to analyze the communication between doctors and patients who were taking bone-stabilizing medication and in rare cases developed osteonecrosis of the jaw as a result. MATERIAL AND

methodsA standardized questionnaire recorded deficits based on patient experiences. These data were used to develop solution strategies for improving doctor-patient communication and the benefit-risk assessment of medication use.

resultsMost patients were satisfied with the information provided by their doctor; however, one in three (29.8%) were not informed about possible side effects, and a quarter (24.6%) only found out about osteonecrosis of the jaw through their own research. Only half (45.7%) were asked about risk factors, and most information materials were rated poorly. The diagnosis took an average of 18.7 months, with many (47.8%) consulting a doctor only when they experienced pain. Quality of life was severely impaired, with daily pain, physical limitations, and negative effects on mental health. About a third (35.3%) reported that their quality of life had deteriorated significantly.

conclusionsFurther research into patient education is necessary. Web-based information brochures, improved follow-up care, and close cooperation with dentists are required. The use of a running sheet, such as the AGSMO running sheet, for individual risk assessment of osteonecrosis of the jaw is recommended. Patients undergoing treatment with bone-stabilizing medication should be monitored closely. Education about osteonecrosis of the jaw must be continued, and the medical profession must be confronted with it.

Indexed as

Bisphosphonate-Associated Osteonecrosis of the JawBone Density Conservation AgentsCommunicationPatient Education as TopicPhysician-Patient RelationsQuality of LifeAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPatient SatisfactionRisk AssessmentRisk FactorsBone Density Conservation Agentsantiresorptive agentsbisphosphonatescommunicationeducationosteonecrosis of the jawquality of life

Identifiers

PMID39497340
PMCPMC11534630

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.